Poorly differentiated thyroid carcinoma (PDTC) is a follicular cell-derived tumour that was recognised as a distinct entity by the World Health Organisation in 2004.
to the more aggressive nature of the disease; thus the overall 10-year survival rate is approximately only 50%. 11, 12 The presence of even a minor component of PDTC in an otherwise WDTC can potentially impact patient prognosis. 13 Molecular studies have demonstrated that PDTCs frequently carry RAS or BRAF mutations, also found in WDTC, as well as additional alterations such as TERT promoter and TP53 mutations; the latter two are thought to be involved in the progression of WDTCs towards the less differentiated PDTC and ATC. 14 The recognition of PDTC as a distinct entity and the introduction of better defined histomorphological criteria facilitated a uniform diagnostic approach for pathologists; however, the cytological diagnosis of PDTC remains problematic. 5 In various studies, approximately one fourth of all PDTC aspirations were reported as malignant but classified as WDTC, and one third were reported as follicular neoplasm/suspicious for a follicular neoplasm (FN/SFN);
such may lead to a less extensive initial procedure (notably lobectomy instead of total thyroidectomy), necessitating additional surgery (i.e., completion thyroidectomy with or without lymph node dissection). [15] [16] [17] [18] The aim of this review is to assess the current literature to investigate the present and future roles of cytology and molecular analysis in the diagnosis of this uncommon but aggressive thyroid carcinoma.
| HISTORICAL PERSPE CTIVE
In 1983, Sakamoto et al proposed the term poorly differentiated thyroid carcinoma to designate a variant of papillary and follicular thyroid carcinomas that was less differentiated and had aggressive behaviour despite lacking features of ATC. The histological diagnosis relied on the presence of a solid, trabecular or scirrhous growth pattern. 9 Shortly thereafter, Carcangiu et al reported on the same entity, restricting the use of the term PDTC to insular patterned tumours in the presence of high-grade features, such as necrosis with the formation of peritheliomatous structures, capsular and vascular invasion, and mitotic activity. 4 (N/C) ratio, and severe crowding was highly predictive of PDTC. Of the total 101 cases in the literature, only 27 (27%) were preoperatively recognised as PDTC. [15] [16] [17] [18] The remaining 74 cases comprised the following diagnoses: poorly differentiated carcinoma, not otherwise specified (NOS; n = 7, 7%); carcinoma, NOS (n = 4, 4%); PTC (n = 10, 10%); medullary thyroid carcinoma (MTC; n = 3, 3%); follicular variant-PTC (n = 13, 13%); suspicious for PTC (n = 1, 1%); FN/SFN (n = 34, 33%); and lastly, atypia of undetermined significance/follicular lesion of undetermined significance (n = 2, 2%; Figure 2 ). 
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The specific diagnosis of PDTC or PDC, NOS was made in only 34% of cases. Overall, the lack of accepted criteria for diagnosing PDTC on FNA material reflects the difficulty in accurately transferring the histological diagnostic criteria of PDTC onto cytological criteria. The reason is that the histological criteria of PDTC overlap in cytology with features of WDTC. Convoluted raisinoid nuclei can be found in a variety of conditions, mainly PTC, and are not specific for PDTC. In addition, the frequent coexistence of a WDTC component can easily confound the diagnosis of PDTC on FNA. 26 Moreover, an oncocytic variant of PDTC has been described at the histological level, raising the additional challenge of distinguishing between PDTC and FN/SFN, oncocytic type ( Figure 4) . 27, 28 At best, the diagnosis of PDTC can be suggested in a subset of FNA cases, but consistent accurate diagnosis based upon cytomorphology has yet to be achieved.
Indeed, while different series have shown a variable distribution of cases according to TBSRTC, the overall percentage of PDTC cases, which are accurately recognised on FNA samples, has not improved over time ( Figure 5 ). For the differential diagnosis of PDTC with MTC or secondary neoplasms, immunostaining on cytology slides or on cell block material can effectively discriminate between these possibilities: PDTC is immunoreactive for thyroglobulin and, unlike MTC, it is negative for calcitonin and carcinoembryonic antigen (CEA). 26, 29 However, immunohistochemistry is useless in differential diagnosis with other thyroid cancers of follicular derivation: PAX-8 and TTF-1 are used to prove thyroid origin in differential diagnosis with secondary thyroid neoplasms, but they are not speficic for PDTC.
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| MOLECULAR FEATUR ES
Less differentiated thyroid carcinomas have been shown to harbour a higher mutation burden. 14, [30] [31] [32] In cases of PDTC, the median number of mutations was found to be two. 30 14,32
TERT mutations occur as a subclonal event in PTC, while they seem to be clonal in PDTC and ATC; therefore, they are considered a potential step in the development of aggressive thyroid cancer. 14, 30 TP53 mutations, which are extremely rare in PTC and FTC, are reported in 10%-26% of PDTC; they seem to play an important role in the dedifferentiation of WDTCs, and they are regarded as late events in tumour evolution. 30, 33 Accordingly, in tumours presenting both papillary and undifferentiated components, TP53 mutations have been found only in the undifferentiated component. 34 Mutations in the eukaryotic translation initiation factor EIF1AX are present in 11% of PDTC: these mutations are reported in only 1% of PTC, where they occur in a mutually exclusive manner with BRAFV600E and RAS mutations; 30 in addition, using next-generation sequencing, Landa et al identified a number of novel genes that can be mutated in PDTC, at frequencies of 1%-4%. 30 When microRNA expression profiles were investigated, miR-150, miR-183-3p, miR-221 and miR-222 were the most dysregulated microRNAs, with a promising role for distinction between WDTC and PDTCs. Recently, systemic therapies using tyrosine kinase inhibitors (sorafenib and lenvatinib) have been approved for radioiodine-refractory WDTC; 38,39 these drugs should then be considered for use in progressive cases of PDTC that are radioiodine-refractory. 
| CONCLUSIONS
